Pasithea Therapeutics Announces Financial and Business Results for the Fourth Quarter and Full Year 2021 and Business Update for 2022
30. März 2022 16:15 ET
|
Pasithea
-- Cash Balance of $52.9 million to fund operations well into 2024 ---- Initiation of a drug development program in schizophrenia ---- Initiation of a drug development program in multiple sclerosis...
Pasithea Therapeutics Announces Collaboration with The Glimpse Group
08. März 2022 08:00 ET
|
Pasithea
- The Glimpse Group is a Virtual Reality and Augmented Reality platform company - Partnership will allow Pasithea to co-develop VR environments for patients with psychiatric disorders MIAMI...
Pasithea Therapeutics Announces Plans to Open Three New Clinics in the UK by Mid-2022
24. Februar 2022 08:00 ET
|
Pasithea
-- Each clinic expected to contribute an estimated USD$5 million (£4 million) annually in revenue -- -- New London locations will provide pharmacy services, ketamine therapy, and other psychiatric...
Pasithea Therapeutics Strengthens its Scientific Advisory Board with the Appointment of Preeminent Scientist Dr. Daniel Weinberger
09. Februar 2022 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., Feb. 09, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of...
Pasithea Therapeutics Initiates New Chemical Entity Drug Development Program in Multiple Sclerosis
03. Februar 2022 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., Feb. 03, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of new...
Pasithea Therapeutics Announces Opening of Mental Health Clinic in Los Angeles and Broadens Focus Beyond Ketamine Treatments
26. Januar 2022 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of...
Pasithea Therapeutics Opens Second Ketamine Therapy Clinic in the United Kingdom
21. Dezember 2021 08:00 ET
|
Pasithea
MIAMI BEACH, Fla., Dec. 21, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (NASDAQ: KTTA) (“Pasithea” or the “Company”), a novel biotechnology company focused on the research and discovery of...
Pasithea Therapeutics Expands its Mobile Clinics into Florida and Nevada
01. Dezember 2021 08:00 ET
|
Pasithea
-- Pasithea Clinics commences in-home IV ketamine infusion therapy in Florida and Nevada -- -- Treatments conducted by board-certified medical professionals -- -- Expansion to additional U.S. cities...
Pasithea Therapeutics Corp. Announces Closing of $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
29. November 2021 17:45 ET
|
Pasithea
MIAMI BEACH, Fla., Nov. 29, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of...
Pasithea Therapeutics Corp. Announces Pricing of a $30.4 Million Private Placement Priced at a Premium to the Market Under Nasdaq Rules
24. November 2021 08:52 ET
|
Pasithea
MIAMI BEACH, Fla., Nov. 24, 2021 (GLOBE NEWSWIRE) -- Pasithea Therapeutics Corp. (Nasdaq: KTTA; KTTAW) (“Pasithea” or the “Company”), a biotechnology company focused on the research and discovery of...